Memantal tablets 10mg, No. 30
Expiration Date: 05/2027
Russian Pharmacy name:
Меманталь таблетки 10мг, №30
Dementia of moderate to severe severity in Alzheimer's disease.
Inside, 1 time a day, at the same time, regardless of food intake.
The dosage regimen is set individually. It is recommended to start treatment with the appointment of the minimum effective dose. Prescribe the drug during the 1st week of therapy (days 1-7) at a dose of 5 mg / day, during the 2nd week (days 8-14) - at a dose of 10 mg / day, during the 3rd week (days 15-21) - at a dose of 15 mg / day, during the 4th week (days 22-28) - at a dose of 20 mg / day. The maximum daily dose is 20 mg.
Special patient groups
Patients over 65 years of age, as well as patients with Cl creatinine 50Ц80 ml / min, do not require dose adjustment. In patients with moderate renal failure (Cl creatinine 30Ц49 ml / min), the daily dose is 10 mg. In the future, if the drug is well tolerated for 7 weeks, the dose can be increased to 20 mg according to the standard scheme.
Instructions for dividing a tablet
Place the tablet with the rounded side up on a hard surface. Press with the index and thumb of one hand on opposite sides of the tablet, continue to apply pressure with your fingers until the tablet breaks into 2 parts (see picture).
| Film-coated tablets | 1 tab. |
| active substance: | |
| memantine hydrochloride | 10 mg |
| Excipients | |
| core: lactose monohydrate - 149.75 mg; MCC - 27.1 mg; talc - 11.15 mg; colloidal silicon dioxide - 1.25 mg; magnesium stearate - 0.75 mg | |
| film shell: OpadryЃ white (lactose monohydrate - 2.16 mg, hypromellose - 1.68 mg, titanium dioxide - 1.56 mg, macrogol 4000 - 0.6 mg) - 6 mg |
hypersensitivity to the drug;
severe renal dysfunction (Cl creatinine <5-29 ml / min);
severe liver failure;
lactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption (the drug contains lactose monohydrate);
pregnancy;
breast-feeding;
children under 18 years of age (efficacy and safety have not been established).
With care: thyrotoxicosis; epilepsy; convulsions (including history); concomitant use of other NMDA receptor antagonists (amantadine, ketamine, dextromethorphan); the presence of factors that increase the pH of urine (a sharp change in diet, intake of large amounts of alkaline gastric buffers); severe urinary tract infections; a history of myocardial infarction; heart failure III Ц IV functional class (NYHA classification); uncontrolled arterial hypertension; renal and hepatic impairment.